The Hippo

HOME| ADVERTISING | CONTACT US|

Valcyte for Cytomegalovirus in Children Manchester NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Henry A Plantier, MD, FAAP
89 Cypress St
Manchester, NH
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 1958

Data Provided by:
Butler James S MD
(603) 669-0831
130 Tarrytown Road
Manchester, NH
 
Peter Michael Clemons
(603) 695-2790
4 Elliot Way
Manchester, NH
Specialty
Pediatric Endocrinology

Data Provided by:
Conway James F Jr PHYS
(603) 669-9200
4 Elliot Way
Manchester, NH
 
Phelps Rick D PHYS
(603) 669-9200
4 Elliot Way
Manchester, NH
 
Cheung Peter T MD
(603) 641-5800
1050 Perimeter Road Suite 501
Manchester, NH
 
Selleck WM PHYS
(603) 669-9200
4 Elliot Way
Manchester, NH
 
Friedenberg David S MD
(603) 641-5800
1050 Perimeter Road Suite 501
Manchester, NH
 
Voroshilova Olga MD
(603) 641-5800
1050 Perimeter Road
Manchester, NH
 
Munoz John J PHYS
(603) 669-9200
4 Elliot Way
Manchester, NH
 
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu